Sudo Biosciences

Sudo Biosciences is a private, pre-revenue biotech advancing a pipeline of novel TYK2 inhibitors for immune-mediated and neurological diseases. The company's lead asset, SUDO-550, has reported positive Phase 1 results and represents a differentiated, brain-penetrant approach targeting conditions like multiple sclerosis. Backed by experienced leadership and investors, Sudo leverages a precision drug design strategy anchored in human genetics and translational biology to develop potentially transformative therapies.

Precision design of brain-penetrant allosteric TYK2 inhibitors, leveraging medicinal chemistry, translational biology informed by human genetics, and a patient-centered development approach.

Sudo competes in the evolving TYK2 inhibitor space against an approved drug (deucravacitinib) and several clinical-stage candidates. Its differentiation lies in a brain-penetrant allosteric profile aimed at neurological indications, a niche with fewer direct competitors but high scientific and clinical hurdles.